Insiders Enjoy US$1.7m Return After Buying Corvus Pharmaceuticals Stock

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) insiders who acquired shares over the previous 12 months, can probably afford to ignore the recent 10% decline in the stock price. After accounting for the recent loss, the US$1.03m worth of shares they purchased is now worth US$2.70m, suggesting a good return on their investment.

While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.

View our latest analysis for Corvus Pharmaceuticals

Corvus Pharmaceuticals Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by Co-Founder Richard Miller for US$1m worth of shares, at about US$1.73 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$4.52. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

Corvus Pharmaceuticals insiders may have bought shares in the last year, but they didn't sell any. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership Of Corvus Pharmaceuticals

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data suggests Corvus Pharmaceuticals insiders own 0.7% of the company, worth about US$2.1m. We consider this fairly low insider ownership.

So What Do The Corvus Pharmaceuticals Insider Transactions Indicate?

There haven't been any insider transactions in the last three months -- that doesn't mean much. However, our analysis of transactions over the last year is heartening. We'd like to see bigger individual holdings. However, we don't see anything to make us think Corvus Pharmaceuticals insiders are doubting the company. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Case in point: We've spotted 4 warning signs for Corvus Pharmaceuticals you should be aware of, and 2 of them are a bit concerning.

But note: Corvus Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.